(Shared Conference with World Preclinical Congress and IO Pharma Congress)

Cambridge Healthtech Institute’s Inaugural

Small Molecules for Immuno-Oncology Therapeutics

Activating the Immune System with Drug-like Orally Bioavailable Compounds to Combat Cancer

June 19-20, 2019


Small molecule agents as opposed to biologics that steer or enable the immune system to attack cancer cells, represent an emerging area of R&D focus in the oncology drug development industry. Small molecules are being investigated as stand-alone agents and synergistically with approved biologics because of the ability of small molecules to reach intracellular targets and the greater patient convenience offered by their oral bioavailability. Targeting non-redundant and/or intracellular pathways with small molecules is highly desirable because there is still a large proportion of patients who are not responsive to the current IO biologics-based therapies. However, small molecule drug development has unique challenges such as chemistry lead optimization decisions and how to find molecules against non-enzymatic, less druggable ‘protein-protein interaction’ targets, which describe many of the IO targets. Join fellow medicinal chemists, discovery biologists, pharmacologists, immunologists and oncology researchers to stay abreast of this burgeoning field and share strategies for tackling common challenges.

SMALL MOLECULE INHIBITORS OF IMMUNO-ONCOLOGY CHECKPOINT BLOCKADE

PDL1 Small Molecule Inhibitor, CA170

Hongwei Wang, MD, PhD, Executive Medical Director, Curis, Inc.

MNK1/2 Inhibitors as Modulators of PDLI Levels

Kevin Webster, PhD, Senior Vice President, Cancer Biology, Effector Therapeutics

INNATE IMMUNE SYSTEM ACTIVATORS: AGONISTS FOR STING, TLRs, ROR

Discovery and Characterization of E7766, a Novel Macrocycle-Bridged STING Agonist with Pan-Genotypic and Potent Antitumor Activity

Kuan-Chun Huang, PhD, Principal Scientist, Discovery Oncology, Eisai Inc.

Molecular Pharmacology of a New STING Agonist

Gottfried Schroeder, PhD, Senior Scientist, Department of Pharmacology, Merck Research Labs- Boston

STING Agonists

Joshi Ramanjulu, PhD, Senior Director, Drug Discovery, GlaxoSmithKline

TARGETING IMMUNO-METABOLISM FOR CANCER

Updates on IDO1 Inhibitor in Phase I Clinical Trials

Frank Charles Dorsey, Ph.D., Senior Research Scientist, Cancer Signaling and Metabolism, Eli Lilly & Co.

AHR Antagonists

Karen McGovern, PhD, VP, Drug Discovery, Kyn Therapeutics

Targeting the IDO Pathway: Arylhydrocarbon Receptor Antagonist

Sheena Pinto, PhD, Senior Scientist, Drug Discovery, PheneX Pharmaceuticals

Arginase Inhibitors

Niu Shin, PhD, Associate Director, Pharmacology, Incyte Inc.


For more details on the conference, please contact:
Anjani Shah, PhD
Conference Director
Cambridge Healthtech Institute
Email: ashah@healthtech.com

For partnering and sponsorship information, please contact:


Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com